BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20635167)

  • 1. Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection.
    Kim R; Menon N; Aucejo F
    Med Oncol; 2011 Dec; 28(4):1044-7. PubMed ID: 20635167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.
    Rowe IA
    Hepatology; 2010 Sep; 52(3):1171-2. PubMed ID: 20812364
    [No Abstract]   [Full Text] [Related]  

  • 3. Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation.
    Kim R; Aucejo F
    J Gastrointest Cancer; 2011 Mar; 42(1):50-3. PubMed ID: 20714941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular carcinoma: sorafenib before liver transplantation?
    Braillon A
    Hepatology; 2010 Jun; 51(6):2232-3. PubMed ID: 20041410
    [No Abstract]   [Full Text] [Related]  

  • 5. Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma.
    Borentain P; Gregoire E; Hardwigsen J; Garcia S; Durieux O; Le Treut YP; Gérolami R
    Clin Res Hepatol Gastroenterol; 2011 Mar; 35(3):234-6. PubMed ID: 21345761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
    Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
    Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
    Kim R; Byrne MT; Tan A; Aucejo F
    Oncology (Williston Park); 2011 Mar; 25(3):283-91, 295. PubMed ID: 21548473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete Regression of Recurrent Advanced Hepatocellular Carcinoma After Liver Transplantation in Response to Sorafenib Treatment: A Case Report.
    Lee HY; Yang KH; Choi BH; Park YM; Yoon KT; Ryu JH; Chu CW
    Transplant Proc; 2016; 48(1):247-50. PubMed ID: 26915876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.
    Matsuda Y; Ichida T; Fukumoto M
    Med Mol Morphol; 2011 Sep; 44(3):117-24. PubMed ID: 21922382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience.
    Saidi RF; Shah SA; Rawson AP; Grossman S; Piperdi B; Bozorgzadeh A
    Transplant Proc; 2010 Dec; 42(10):4582-4. PubMed ID: 21168742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report.
    Wang Y; Speeg KV; Washburn WK; Halff G
    World J Gastroenterol; 2010 Nov; 16(43):5518-22. PubMed ID: 21086573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib in hepatocellular carcinoma.
    Josephs DH; Ross PJ
    Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era.
    Pfiffer TE; Seehofer D; Nicolaou A; Neuhaus R; Riess H; Trappe RU
    Tumori; 2011; 97(4):436-41. PubMed ID: 21989430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
    Saab S; McTigue M; Finn RS; Busuttil RW
    Exp Clin Transplant; 2010 Dec; 8(4):307-13. PubMed ID: 21143097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
    Yoon DH; Ryoo BY; Ryu MH; Lee SG; Hwang S; Suh DJ; Lee HC; Kim TW; Ahn CS; Kim KH; Moon DB; Kang YK
    Jpn J Clin Oncol; 2010 Aug; 40(8):768-73. PubMed ID: 20494947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of patients with hepatocellular carcinoma for sorafenib.
    Abou-Alfa GK
    J Natl Compr Canc Netw; 2009 Apr; 7(4):397-403. PubMed ID: 19406040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
    Herden U; Fischer L; Schäfer H; Nashan B; von Baehr V; Sterneck M
    Transplantation; 2010 Jul; 90(1):98-9. PubMed ID: 20606568
    [No Abstract]   [Full Text] [Related]  

  • 18. Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib.
    Wich C; Agaimy A; Strobel D; Wissniowski TT; Hartmann A; Ocker M
    World J Gastroenterol; 2010 Jul; 16(28):3592-6. PubMed ID: 20653070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study.
    Teng CL; Hwang WL; Chen YJ; Chang KH; Cheng SB
    World J Surg Oncol; 2012 Feb; 10():41. PubMed ID: 22339891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy?
    Vagefi PA; Hirose R
    J Gastrointest Cancer; 2010 Dec; 41(4):217-20. PubMed ID: 20443078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.